# AbbVie Inc. (ABBV) FY2026 YTD Q2 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001551152-26-000026
- Page: https://plicit.ai/financials/abbv/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 31,992,000,000 US dollars
- **Cost of products sold**: 8,509,000,000 US dollars
- **Gross profit (calculated)**: 23,483,000,000 US dollars
- **Operating expenses (calculated)**: 13,061,000,000 US dollars
- **Operating earnings**: 10,422,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 5,105,000,000 US dollars
- **Earnings before income tax expense**: 5,317,000,000 US dollars
- **Income tax expense**: 1,004,000,000 US dollars
- **Net earnings**: 4,313,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 1,396,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 477,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 595,000,000 US dollars
- **Immunology - Humira**: 1,444,000,000 US dollars
- **Immunology - Rinvoq**: 4,644,000,000 US dollars
- **Immunology - Skyrizi**: 9,988,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 2,051,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 242,000,000 US dollars
- **Neuroscience - Qulipta**: 646,000,000 US dollars
- **Neuroscience - Ubrelvy**: 731,000,000 US dollars
- **Neuroscience - Vraylar**: 1,976,000,000 US dollars
- **Neuroscience - Vyalev**: 457,000,000 US dollars
- **Oncology - Elahere**: 409,000,000 US dollars
- **Oncology - Epkinly**: 186,000,000 US dollars
- **Oncology - Imbruvica**: 1,088,000,000 US dollars
- **Oncology - Venclexta**: 1,541,000,000 US dollars
- **Other Key Products - Linzess**: 578,000,000 US dollars
- **Other Key Products - Mavyret**: 646,000,000 US dollars
- **Undisclosed (calculated)**: 2,897,000,000 US dollars
- **Selling, general and administrative**: 7,210,000,000 US dollars
- **Research and development**: 4,816,000,000 US dollars
- **Acquired IPR&D and milestones**: 1,035,000,000 US dollars
- **Other operating income**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.31 B; to noncontrolling interests: $5.00 M.